Skip to main content

Table 1 Patient characteristics

From: Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody

n = 22

 

Mean ± S.D.

Median

Range

Age (year)

 

66.09 ± 7.78

65

51–80

Sex

 Male

17

   

 Female

5

Body Height (cm)

 

162.84 ± 8.35

163.35

149.00–175.30

Body Weight (kg)

 

58.14 ± 9.11

56.55

40.00–74.00

PS

 0

14

   

 1

6

 2<

2

Type of cancer

 Colon

13

   

 Rectal

7

 Cecum

2

EGFR-targeting antibodies

 Cetuximab

14

   

 Panitumumab

8

No metastatic sites

 One

7

   

 Two

8

 Three or more

7

Involved sites

6

   

 Lung

13

   

 Liver

14

 Lymph nodes

3

 Bone

0

 Peritoneal

7

Median treatment cycle

  

9.30

1.00–23.00

Median treatment duration, weeks

  

9.00

2.00–46.00

Combination of Magnesium oxide formulation

 Yes

11

   

 No

11

Combination regimen

 FOLFIRI base

15

   

 FOLFOX base

2

 CPT-11

2

 Monotherapy

3

Serum Magnesium (mg/dL)

 

2.13 ± 0.22

2.00

1.80–2.60

Serum Calcium (mg/dL)

 

9.96 ± 0.33

9.85

9.50–10.50

Laboratory data

 Neu (/mm3)

 

3716.8 ± 1459.1

3475.0

1380.0–6880.0

 WBC (/mm3)

 

5936.3 ± 1685.9

5450.0

3200.0–10100.0

 PLT (/mm3)

 

207,091 ± 5651

205,500

111,000–330,000

 Hb (g/dl)

 

11.67 ± 1.73

11.55

7.80–14.4

 sCre (mg/dl)

 

0.73 ± 0.31

0.64

0.51–1.88

 AST (IU/l)

 

20.40 ± 4.44

21.00

12.00–28.00

 ALT (IU/l)

 

15.40 ± 7.08

13.50

5.00–30.00

  1. Patients treated with anti-EGFR antibodies = 43; serum Ca level was measured for all patients